Results 11 to 20 of about 701,274 (266)
Medicina, 2022 Background and Objectives: For stage IIIb–IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a ...
Irena Conic +7 more
doaj +1 more source
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival [PDF]
JNCI: Journal of the National Cancer Institute, 2009 Whether progression-free survival (PFS) or overall survival (OS) is the more appropriate endpoint in clinical trials of metastatic cancer is controversial. In some disease and treatment settings, an improvement in PFS does not result in an improved OS.We partitioned OS into two parts and expressed it as the sum of PFS and survival postprogression (SPP).
Kristine R, Broglio, Donald A, Berry
openaire +2 more sources
Outcome of Primary CNS Lymphoma; A Retrospective Analysis
Asian Pacific Journal of Cancer Care, 2022 Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi +3 more
doaj +1 more source
Infectious Diseases and Therapy, 2023 Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu +14 more
doaj +1 more source
Pharmaceutics, 2022 Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet +15 more
doaj +1 more source
Cancer Treatment and Research Communications, 2021 Purpose: From 2011 to 2016, 13 randomized clinical trials with active controls were submitted to U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma.
Manasi Sheth, Jinnie Ko
doaj +1 more source
Prognostic factors and survival study in high-grade glioma in a hospital in Lima, Peru
Revista de la Facultad de Medicina Humana, 2020 Introduction: Gliomas are primary tumors of the central nervous system. They are classifiedfrom grade I-IV, with high grade III and IV being the most frequent and with poor prognosis. Objective: To determine the prognostic factors of survival in patients
Paul Méndez-Aguilar +1 more
doaj +1 more source
Cancer Cell International, 2021 Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini +6 more
doaj +1 more source
Progression‐free survival as a surrogate marker of overall survival [PDF]
Cancer, 2011 The use of progression‐free survival as a surrogate marker of efficacy in cancer treatment has been the subject of much discussion in recent years. However, it should not be considered a surrogate marker for overall survival.
openaire +2 more sources
Contemporary Oncology, 2016 We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski +1 more
doaj +1 more source